



Telomir Pharmaceuticals Is A Biotech Pump And Dump Scheme Remaining In the Preclinical Stage

- Telomir Pharma (TELO) is in the preclinical stage with only one drug, TELOMIR-1, being studied to treat osteoarthritis.
- At the end of 2024, TELO has still not reported results from any earlier announced preclinical mammal studies, suggesting the studies didn't produce good data to report, or they weren't even done.
- Instead, TELO has recently announced preclinical studies on fish and worms which aren't good models for osteoarthritis or diabetes in humans.
- From TELO's statements, it's clear that they are very far from testing TELOMIR-1 in humans, likely years or perhaps never as human trials are not needed for their scheme.
- TELO's founder, Jonnie. R. Williams Sr, has an alarming history of corruption, pump and dumps, and companies that went bankrupt.
- TELO's IPO lock-up expired on 8/7/24 and the pre-IPO investors that bought 28.6M shares at \$0.15 per share can sell at any time.
- TELO is run by a team of insiders, many without biotech backgrounds, that have been a part of Williams' schemes in the past, with many related party transactions.
- TELO's preclinical biotech peers, some also with Mr. Williams as the founder, have market caps below \$30M, which suggests TELO is massively overvalued.
- There have been numerous paid promotions to pump TELO and keep the stock price up.
- TELO has wasted investors' money to pay for a private jet.



Company Overview

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a pre-clinical stage biotechnology company formed in 2021 originally with one full-time employee and eight part-time employees. It went public in February of 2024 at \$7 per share with Kingswood Capital as the underwriter.

The company is developing TELOMIR-1, the first and only molecule designed to modulate telomerase to promote the repair and lengthening of telomeres, thus restoring the possibility of a high fidelity, accurate replication of DNA. It is under investigation to potentially provide a therapeutic intervention against age-related inflammatory conditions.

As stated in the company's April, 2024 investor deck, the drug's focus is on osteoarthritis, with an IND application filing expected in the first quarter of 2025. This is unrealistic, given that the company has not successfully completed their preclinical dog and rat studies. Although these studies started in 2024, no results were reported yet, likely meaning that they failed.

The PRs of the company are rich with buzz-words like "anti-aging" or "age-reversing". The magic of cheating death and delaying old age has always been extremely attractive, and the allure has been a tool by con men since the beginning of humankind.

Pre-IPO Investors Are Up A Whopping 3000% on Their Investment Without The Company Accomplishing Anything Material, Still Being in The Preclinical Stage

What's shocking, is this is a company that hasn't accomplished anything material, is still in the preclinical stage, and doesn't even have any approved patents. However, at the current price of \$5, pre-IPO investors can sell for a 3000%, or 30x, gain. As shown from the company's IPO prospectus filed on 2/12/24, pre-IPO investors bought 28.6M shares at 15c each, and it IPOed 1M shares to uniformed investors at \$7:

	Shares Purchased		Total Consideration		Average Price
	Number	Percent	Amount	Percent	Per Share
	(\$ in millions)				
Existing shareholders	28,609,814	96.6%	\$ 4,155,579	37.3%	\$ 0.15
New investors	1,000,000	3.4%	7,000,000	62.7%	7.00
Total	29,609,814	100.0%	\$11,155,579	100.0%	

Tables of contents

Telomir Pharmaceuticals Is A Biotech Pump And Dump Scheme Remaining In the Preclinical Stage	01
Introducing Telomir's Founder – The Infamous Jonnie Williams	04
Williams Has a Large Stake in Telomir Through Trusts	06
Telomir Is Massively Overvalued for a Biotech Still in The Preclinical Stage	06
Telomir Has Not Reported Data From Earlier Announced Preclinical Mammal Studies – This Suggests The Results Were Bad	07
Telomir Has Questionable Executives With Shady Past	09
Erez Aminov, CEO	09
Dr. Michael Roizen, Scientific Advisor	10
Telomir Insiders Connections with Other Preclinical Penny Stocks	11
Telomir's Inappropriate Use of Company's Funds On A Private Jet	10
Conclusion	13

Source: TELO IPO Prospectus

The lockup expiry was 8/7/24. But if they dump right away, that would crush the stock. Therefore, the company has a continuous promotional campaign to keep the stock up. But once insiders decide to massively start selling – look out below!

Introducing Telomir's Founder – The Infamous Jonnie Williams

Jonnie R. Williams Sr. has a very interesting history. He dropped out of college to work as a car salesman. Later, he had a long history of promoting biotech stocks. Such as Star Scientific, Spectra Pharma, Lasersight, HedgePath (HPPI), CV Sciences (CVSI), TNF Pharma (TNFA), Mira Pharma (MIRA), Telomir Pharma (TELO), and Inhibitor Therapeutics (INTI).

These companies all suffered the same fate as was described in a shareholder lawsuit quoted in a [2014 Newsweek article](#) regarding Williams and his partner, Frank O'Donnell:

The two men followed a similar script in nearly each of their business. They would take over a medical-related product or service company, proclaim it had developed a medical breakthrough without providing reliable data to prove it, pump up the stock price with those false claims, pay themselves generous salaries and options out of proceeds from stock offerings, then sell their shares before leaving behind a company that collapsed in financial ruin.

TELO exactly fits into the above description of Williams' companies.

As stated in a [1988 Boston Globe article](#):

Jonnie R. Williams who "could sell a snowball to an Eskimo", now uses his skills to sell scientific promises.

THE BOSTON GLOBE, FRIDAY, DECEMBER 24, 1988

The selling of scientific promises: profits, problems

New entrepreneurs blur line between business, science

■ MEDICAL
Continued from Page 1

works. Not one has made a substantial profit.

That has not deterred the partners. They have raised almost \$20 million for the companies by arranging for sale of stock to the public. In the process, they have made themselves rich. Other investors have not fared so well.

Defenders of the two men say their efforts help speed new medical ideas into marketable products. And they say investors are agreed of the risks before putting their money in. No one has accused either man of breaking the law.

But O'Donnell and Williams set a new trend of entrepreneurship with operations at the border between American business and biomedical science. And the way they operate that line is causing trouble for people on both sides.

Unlike traditional businessmen, they are not selling proven products. In some cases, it hasn't even been shown that the science even study to turn into products. More than anything else, what they are selling is scientific promise.

The problem for investors is that the two men seem to have found a way to sell promises that usually amounts they make money no matter what happens. The problem for the public is that these men are equipped to exaggerate the promises – the scientists whose research they commercialize – as part of their ventures.

O'Donnell, 38, did not return phone calls to recent works. In an interview in New York, recently Williams, 33, defended his business practices and his partner's. "We invest in start-up ventures," he said. "There's nothing special in that."

Frank J. O'Donnell Jr. is one of a new breed of entrepreneurs who operates at the border between business and biomedical science.

... to give investors lectures. Early on, consultants worked for only small fees.

"This was a very good time we thought," said Alexander S. Nadler, a Harvard Medical School emeritus professor who made a career of films on genetics. "I thought it would be a little like being 'Aristotle Clarke,' the host of PBS's 'Sister Gene' Theater." Nadler said.

O'Donnell depended on his contributions for more than lectures. They provided him with access to their academic power to grant academic credit for watching his taped courses, and they helped coordinate their institutions to let him use their video studios. Among those that provided studios were Johns Hopkins and Harvard-affiliated Beth Israel Hospital.

All in all, O'Donnell's video empire was clearing out more than a dozen medical applications and, according to people who participated, most were failures.

Things began to change in 1985. Apparently, O'Donnell had second thoughts about the venture's prospects, and he backed up with Williams against the middle of that year. He and Williams had organized their first company, CME-GAT Inc., and sold \$12 million worth of stock to it to the public.

In documents the company filed with the SEC to sell the stock, O'Donnell is listed as the chairman, medical director and vice president, and Williams as president and treasurer at \$10,000.

The documents do not mention Columbia Pictures.

Business profits, academic problems

CME-GAT was the two men's first attempt to convert an academic idea into a profit-making venture. It showed them how much money could be made by



Photo: Deborah Green/Letter-Tree photo



Source: Boston Globe

Williams' history of publicly traded companies that used his [patents](#) goes all the way back to 1990 with his company, Star Tobacco. Star Tobacco was a discount cigarette maker which then became Star Scientific, a dietary supplement company. Similar to TELO, Star Scientific also focused on age-related inflammation issues with their primary product, Anatabloc.

In 2014, Star Scientific got in hot water with the FDA. As stated in [this article](#) from 2014:

Star Scientific Inc... announced in late December that it had received a warning from the U.S. Food and Drug Administration for two of its consumer products.

The FDA's letter to the company states that anatabine, used in two of its products — Anatabloc and CigRx — is a new dietary ingredient that required premarket notification to the agency. The letter also states that the company's products are unapproved new drugs... Anatabloc, Star Scientific's primary product, is an anti-inflammatory drug.

In 2013, Williams found himself and Star Scientific in the middle of a national [corruption scandal](#) involving Virginia Governor Bob McDonnell and his wife.

As stated in [this news story](#) from 2014:

NEWS

Witness: Jonnie Williams called sobbing after FBI interview

The case indictment states that Bob McDonnell used the payments from Mr. Williams to "legitimize, promote, and obtain research studies for Star Scientific".

Jonnie R. Williams Sr. received immunity in the case.

Star Scientific changed its name to Rock Creek Pharmaceuticals and focused on chronic inflammation diseases and nicotine addiction. By 2016, Rock Creek Pharmaceuticals, which was preparing for a Phase 1b trial, filed for [Chapter 7 bankruptcy](#). RCP Development, a subsidiary of Rock Creek Pharmaceuticals, also filed for Chapter 7 bankruptcy. RCP Development held a patent developed by Mr. Williams for another anti-inflammation drug.



Williams Has a Large Stake in Telomir Through Trusts

His control of TELO is not direct but through two trusts. One of them is Bay Shore Trust which has a controlling stake of more than 30% of TELO's outstanding shares.

As stated in the [2023 annual report](#):

Our founding stockholders, which include two trusts for the benefit of the family of our founder Johnnie R. Williams, Sr., as well as MIRALOGX, collectively own in excess of 30% of our issued and outstanding common stock. Brian McNulty acts as the trustee for such trusts.

Also stated in the annual report, is the other trust controlled by Williams is Starwood Trust. On 12/12/24, TELO announced in a PR that they raised \$1M at \$7 per share through Starwood Trust. The report states:

The restricted shares further emphasize The Starwood Trust's confidence in the company's long-term strategy and potential.

We disagree with the company's opinion. 140K shares is nothing compared to the 20M+ shares that Williams and his crew and family owns.

Telomir Is Massively Overvalued for a Biotech Still in The Preclinical Stage

Compared to other early stage biotechs, some also founded by Jonnie Williams, TELO is massively overvalued with its \$200M market cap. The following are beginning stage biotechs with much smaller market caps.

Comparing Telomir's Market Cap to Comparable Biotechs				
Biotech Symbol	Trial Stage	Type of Drug	Current Market Cap	Notable Insiders
TELO	Preclinical	Anti-aging/anti-inflammatory	\$150M	Founder: Jonnie Williams, CEO: Erez Aminov Chief Scientific Advisor: Dr. Itzchak Angel
TNFA	Ph 1 & 2a	Anti-aging/anti-inflammatory	\$4M	Founder: Jonnie Williams President: Dr. Mitchell Glass
MIRA	Preclinical	Neuropathic Pain	\$20M	Founder: Jonnie Williams, CEO: Erez Aminov Chief Scientific Advisor: Dr. Itzchak Angel
LGVN	Ph 1 & 2a	Anti-aging	\$30M	CEO: Dr. Mohamed Hashad

Compare TELO to a related company, also founded and owned by Williams, Mira Pharmaceuticals (MIRA), another biotech in the preclinical stage. MIRA has a sub \$20M market cap. MIRA also has the same CEO and Chief Scientific Advisor that TELO has. The CEO, Erez Aminov, is Williams son-in-law.

TNF Pharmaceuticals (TNFA), another company founded and owned by Mr. Williams, has a tiny market cap of only about \$4M with over \$10M in cash. Like TELO, it's also developing an anti-inflammatory drug for age-related conditions. Both TELO and TNFA shared Dr. Chris Chapman as an executive. He was the President and Chief Medical Officer of TNFA, a part-time Chief Executive Officer and Chairman of TELO until August 2024, and the Chairman of MIRA. He passed away in August of 2024

From a [recent PR](#) on 8/21/24 titled:

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

It states:

Clinical study of MYMD-1 in sarcopenia/frailty met primary endpoints for significantly reducing chronic inflammatory markers with statistical significance

Another comparable biotech to TELO, is Longeveron (LGVN). It's also a biotech that is developing anti-aging drugs. As LGVN is described on [Yahoo Finance](#):

“develops cellular therapies for aging-related and life-threatening conditions”.

LGVN has net cash of about \$20M and has a relatively tiny market cap of only about \$30M. Again, another early stage, similar biotech with a valuation a fraction of what TELO's is.

We believe as insiders start selling their shares, over time TELO will move down to the market cap of its peers.

Telomir Has Not Reported Data From Earlier Announced Preclinical Mammal Studies – This Suggests The Results Were Bad

It is quite remarkable that despite announcements of numerous “ground-breaking” and “miraculous” preclinical data in 2024, TELO has not reported any results from mammal studies to this date. In addition to in-vitro cell culture research, TELO reported only results from zebra fish and from worm studies, which are further away from humans and therefore is going backwards in the drug development process.


While TELO proudly trumpeted the initiation of three mammal studies (two in dogs and one in rats) and all these studies should have been already completed, not any results were presented by this company that never misses opportunity to excite investors with “ground-breaking data”. This leads us to believe that either TELO misled investors by never starting these studies, or TELO completed the studies but the results were really bad and, therefore, were hidden from the public.

Let's look at the details.

On 4/2/24, TELO [announced](#) that they will share promising preclinical data at the National Press Club. An analysis of this presentation, [presented](#) at the National Press Club on 4/15/24, shows that only plans for preclinical studies were shared that the rat and dog studies were started in April/May of 2024.


The most recent [corporate presentation from August 2024](#) stated that both Rat and Dog studies were initiated in Q1 2024, which is even a one quarter earlier than the timelines from the April 15th presentation.

Pre-clinical work is underway and initial IND is expected to be filed in Q1 2025



This presentation also features dog and rat pictures and videos, but no other data. The only preclinical data shared were in-vitro cell culture studies, obtained in collaboration with Frontage Labs.

We failed to find any data published for rat and dog studies, presumably started in Q1 or Q2 2024. Instead, TELO published a [PR on 11/21/24](#), disclosing an EU based worm study on aging, and another [PR on 12/3/24](#) disclosing an India based zebra fish study related to diabetes. But that is going even further away from human-like animals – where are the results of US based mammal studies in dogs and rats?



Source: TELO 4/12/24 Investor Deck

On 8/20/24, TELO published a PR about the “miraculous recovery” of Telomir-1 pill on two rescue dogs in Florida, which were not related to the canine study by Argenta Midwest Labs. It states:

“New study reveals promising results for age reversal pill on dogs,” the transformative potential of Telomir-1 was showcased through the stories of Zeus and Benson, two senior dogs from Donte’s Den rescue organization in Myakka City, Florida.”

This anecdotal data on two animals which do not even have real owners, and therefore are hard to track, should not impress anyone. This just shows that TELO is desperate to present any story as data in the absence of results of the preclinical studies promised earlier

On 5/30/24, [TELO published another PR](#) about the initiation of four Beagle Dogs study for 63 Consecutive Days to check on Telomir-1 effect on aging. 63 days should have ended in early July 2024. No results of this study have been revealed yet.

TELO, with a market cap of over \$100M and a promise to start clinical study in humans in 2025, has not even proven its technology in an osteoarthritis mammal animal model. There is really no meaningful data on Telomir-1, so we are very skeptical of TELO's ability to approach the FDA for any clinical study discussion in 2025. We believe that plans of clinical studies in humans in 2025 is just a stock pump, similar to the empty promises of rat and dog studies in 2024.

Frontage Laboratories also has data mishandling problems, It was fined \$125K in 2023 by the United States Attorney for violations of the Controlled Substance Act. Violations sited are record-keeping violations; failure to document correct amount of certain controlled substances on hand; failure to record the date and quantity received among other violations.

TELO is just continuing to put out PRs about preclinical study results and says they will start new preclinical studies. From TELO's own statements, it appears that they won't do any human studies for a very long time, perhaps years, and maybe never if insiders are able to sell all their shares and finish with the scheme.

Telomir Has Questionable Executives With Shady Past

TELO has many questionable characters working on its executive team. Many have worked with Williams in the past. Some have little to no biotech experience.

Erez Aminov, CEO

On 8/12/24, Erez Aminov [replaced](#) TELO's former CEO, Dr. Christopher Chapman, after he passed away. In late 2022, Aminov started providing consulting services to William's founded companies like MIRA, TNFA, INTI, and TELO. He's also the CEO of MIRA.

Aminov is William's son-in-law. He had an [extravagant wedding](#) with William's daughter, Rachel Williams, featured in Vogue Magazine in 2023. Aminov doesn't have a biotech or medical background, other than working for Williams' companies. He is a Florida real estate agent, shown here. He owns a real estate investment company, [S&W Investments](#), with a Florida radiologist Denil Shekhat who is on the board of MIRA.

In the early 2000s, Aminov worked as a diamond reseller. He was [sued](#) in 2007 for not paying for the diamonds. Around 2006-2007, after initially stalling, he stopped paying for the diamonds and quit the business. According to court documents, he claimed that he was defrauded by Russian and Kazakh clients who he hadn't met but was selling diamonds to.



Dr. Michael Roizen, Scientific Advisor

Dr. Roizen was hired by TELO as a key scientific advisor on age reversal. Roizen is the Chief Medical Consultant to Dr. Oz, and both have written a number of books on age reversal secrets. Dr. Oz is known to peddle unproven nutritional supplements on his show.

Four pages on TELO's August 2024 investor deck are straight from Dr. Roizen's 2022 book: [The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow](#). One page shown below:

ADVANTAGES OF ELONGATING TELOMERES

- Stress **shortens** telomeres
- People who regularly eat sugar laden and processed food have **shorter** telomeres
- People who regularly do extreme physical activity have **shorter** telomeres
- Astronauts have **shorter** telomeres
- People who have sun burns or who smoke or vape have **shorter** telomeres
- People who regularly have short sleep times have **shorter** telomeres
- **VS**
- People who regularly eat healthily have **longer** telomeres
- People who regularly meditate have **longer** telomeres
- People who regularly have friends have **longer** telomeres
- People who regularly do moderate physical activity have **longer** telomeres
- People who regularly sleep 6.5 to 8.5 hours a night have **longer** telomeres
- People who regularly have sex have **longer** telomeres

↓

Roizen, M. Linneman, P., & Ratner, A. (2022). The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow. National Geographic.

Nasdaq: TELO 10



In June of 2024, TELO's Chief Financial Officer [resigned](#), and the company replaced him with a new Chief Financial Officer that also served as Chief Financial Officer of MIRA. Upon the death of Dr. Christopher Chapman, three board members [resigned](#) and TELO replaced Dr. Chapman with the Chief Operating officer from MIRA and appointed three new board of directors all affiliated with MIRA as well as directors.

In November of 2024, Michael Jerman a Board of Directors member and Chair of the Audit Committee of TELO [resigned](#). He was replaced by another former board of directors of MIRA, Matthew Pratt Whalen as the Chair of the Audit Committee. There is no mention in his biography on TELO's [website](#) or in Q224 stating that he is affiliated with MIRA but he is listed as director on MIRA's [website](#). This seems like TELO is omitting a material public information of a related party and who is going to oversee proper presentation of financial statements for inventors. The other two new directors properly disclosed their relationship with MIRA. Matthew Pratt Whalen should have similar disclosure of his relationship with a related party, especially since he is going to be the Head of Audit.

If he is failing to disclose his relationship with MIRA how can anybody trust him to disclose financial information that might be material for investment decisions of TELO?

[Dr. Matthew P. De Giudice](#) a radiologist who also comes from MIRA and was appointed as a director during the resignation of previous board of directors' members in August of 2024 voted by the rest of the board to be a member of the Audit Committee.

When the directors that are responsible for making sure that the company's financial statements are properly vetted resign—it is a major red flag for investors. Who else would know better about what is going than a Chair of the Audit?

And why would a radiologist be an appropriate appointment as a member of the Audit Committee?

Telomir Insiders Connections with Other Preclinical Penny Stocks

MIRALOGX, LLC and Bay Shore Trust are connected to [MIRA Pharmaceuticals, Inc](#) (MIRA) and MyMD Pharmaceuticals which changed its name to TNF Pharmaceuticals (TNFA). Both are penny stocks that are licensing their patents from Mr. Williams and his intellectual property holding company MIRALOGX, LLC. MIRA [states](#) that MIRALOGX, LLC and Bay Shore Trust are related parties.

TNFA also has a Limited License Agreement with MIRA for Supra-CBD and MIRA1a product candidates. TNFA curiously enough has the same corporate address in Baltimore as TELO with the only exception is the suite number at the filing of their IPO prospectus.

From [TNFA](#) 8-K:



TNF Pharmaceuticals, Inc.

855 N. Wolfe Street, Suite 623

Baltimore, MD

(Address of principal executive offices)

TELO IPO Prospectus:

"Our corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205"

As recently as Q224 TELO's main office was in Tampa, Florida where their administrative and accounting offices are, and they were sharing the space with MIRA along the way with mutual directors and executives.

Telomir Needs Cash Soon

As of right now TELO will have to raise cash going into 2025. Cash on hand as of 9/30/24 was at only \$800K.

On 9/27/24 TELO [filed](#) an 8-K stating that they entered into a Promissory Note and Loan Agreement with Starwood Trust, a related party for \$5M that they are planning to draw at the end of first quarter of 2025. Starwood Trust is also controlled by Mr. Williams. This financing arrangement is very similar to the one they got with Bay Shore Trust which had 2,439,025 warrants at \$3.73 per share issued to Bay Shore as part of a loan conversion deal. The exercising of the warrants would raise about \$9M for the company.

On 12/12/24, TELO [announced](#) that they raised \$1M in equity funding from Starwood, which is just short term emergency funding.

Telomir's Inappropriate Use of Company's Funds On A Private Jet

A 1.71% holder of TELO is [Supera Aviation I, LLC](#), which is a private jet that is registered in Tampa, Florida. Tampa is the same city TELO used to operate from until September 2024. Super Aviation, LLC is also used by MIRALOGX, LLC. As stated in its [Q224 quarterly report](#), TELO had an agreement with MIRALOGX, LLC for shared lease cost of this airplane since April, 2023 and paid a monthly contribution for it.

For the year ended 2023, TELO spent \$1.8 million on Related party travel costs which is more than they spent on R&D at \$1.6 million. TELO claims to use it for business related purposes. The general rule is that if a company is serious about developing their drug the management will most likely spend all the cash they have on R&D, not on private jets that are owned by insiders.



Conclusion

In our opinion TELO is going to go below \$1 next year and will be one of those companies that needs to do a reverse stock split to keep its listing on the NASDAQ. The company hasn't published data on its rat or dog studies, if they happened at all. In its place, the company took a step backwards in drug discovery by doing preclinical studies with fish and worms. We don't expect the company will file for an IND next year, and they will continue to do more preclinical studies for years to come.

The history of TELO's founder, Jonnie R. Williams Sr., and his relationship with other companies who shared the same office space, executives and board members while paying for his private plane are also red flags. In the short-term they need cash to cover operations going into 2025 and we see continued dilution. We don't expect they will ever develop the drug, as we believe this is just another Jonnie Williams scheme to enrich insiders.